Eikon Therapeutics Inc. (EIKN)
EIKN trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | EIKN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2026 |
| SEC CIK | 0001861123 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials
New registrant: no annual report filed under this company yet.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $98.5M cash; operating cash flow -$70.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 54,186,095 (2026-11-02). | Cover page 2026-11-02 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, San Jose, California, United States | PCAOB Form AP 2026-04-08 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $44.7M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$86.1M | -$69.2M | $98.5M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q3 2026 2026-06-30 | Not filed | -$88.4M | -$65.0M | $142.6M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q3 2026 2026-03-31 | Not filed | -$83.0M | -$89.8M | $161.2M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q3 2026 2025-09-30 | Not filed | -$71.1M | -$59.5M | $104.9M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q3 2026 2025-06-30 | Not filed | -$105.2M | -$32.7M | $136.6M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q3 2026 2025-03-31 | Not filed | -$68.2M | -$54.5M | $204.6M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B4 | 2026-02-05 |
| Latest annual report | 10-K | 2026-03-30 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 69 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +1.4% |
| 1 month | -11.0% |
| 3 months | -42.1% |
| Year to date | Not enough price history |
| 1 year | Not enough price history |
| From 52-week high | -63.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SCTX | Scribe Therapeutics Inc. | $15.37 | -6.05% | $291.1M |
| AGMB | AgomAb Therapeutics NV | $5.97 | -6.13% | $294.0M |
| XFOR | X4 Pharmaceuticals Inc. | $2.83 | -9.29% | $289.0M |
| EDIT | Editas Medicine Inc. | $1.87 | -13.82% | $288.6M |
| TRXB | TRex Bio Inc. | $10.77 | -21.21% | $295.6M |
| IPSC | Century Therapeutics Inc. | $1.64 | -0.61% | $297.8M |
| AGEN | Agenus Inc. | $6.29 | -6.54% | $284.6M |
| KYTX | Kyverna Therapeutics Inc. | $4.76 | -5.74% | $300.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier